Recent Findings from University of Helsinki Provide New Insights into Cancer Gene Therapy (Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients)
By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Research findings on Biotechnology are discussed in a new report. According to news reporting originating in Helsinki, Finland, by NewsRx journalists, research stated, "Oncolytic adenoviruses and certain chemotherapeutics can induce autophagy and immunogenic cancer cell death. We hypothesized that the combination of oncolytic adenovirus with low-dose temozolomide (TMZ) is safe, effective, and capable of inducing antitumor immune responses."
The news reporters obtained a quote from the research from the University of Helsinki, "Metronomic low-dose cyclophosphamide (CP) was added to selectively reduce regulatory T-cells. Preclinically, combination therapy inhibited tumor growth, increased autophagy, and triggered immunogenic cell death as indicated by elevated calreticulin, adenosine triphosphate (ATP) release, and nuclear protein high-mobility group box-1 (HMGB1) secretion. A total of 41 combination treatments given to 17 chemotherapy-refractory cancer patients were well tolerated. We observed anti-and proinflammatory cytokine release, evidence of virus replication, and induction of neutralizing antibodies. Tumor cells showed increased autophagy post-treatment. Release of HMGB1 into serum--a possible indicator of immune response--increased in 60% of treatments, and seemed to correlate with tumor-specific T-cell responses, observed in 10/15 cases overall (p=0.0833). Evidence of antitumor efficacy was seen in 67% of evaluable treatments with a trend for increased survival over matched controls treated with virus only."
According to the news reporters, the research concluded: "In summary, the combination of oncolytic adenovirus with low-dose TMZ and metronomic CP increased tumor cell autophagy, elicited antitumor immune responses, and showed promising safety and efficacy."
For more information on this research see: Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients. Molecular Therapy, 2013;21(6):1212-23. (Elsevier - www.elsevier.com; Molecular Therapy - www.elsevier.com/wps/product/cws_home/622922)
Our news correspondents report that additional information may be obtained by contacting I. Liikanen, Cancer Gene Therapy Group, Dept. of Pathology and Transplantation laboratory, Haartman Institute, University of Helsinki, Helsinki, Finland. Additional authors for this research include L. Ahtiainen, M.L. Hirvinen, S. Bramante, V. Cerullo, P. Nokisalmi, O. Hemminki, I. Diaconu, S. Pesonen, A. Koski, L. Kangasniemi, S.K. Pesonen, M. Oksanen, L. Laasonen, K. Partanen, T. Joensuu, F. Zhao and Kaner (see also Biotechnology).
Keywords for this news article include: Antineoplastics, Biotechnology, Pharmaceuticals, Drugs, Europe, Finland, Helsinki, Oncology, Adenovirus, Temozolomide, Alkylating Agents, Cancer Gene Therapy.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC